MCID: SCN052
MIFTS: 41

Secondary Adrenal Insufficiency

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Secondary Adrenal Insufficiency

MalaCards integrated aliases for Secondary Adrenal Insufficiency:

Name: Secondary Adrenal Insufficiency 49 69
Hypocortisolism Secondary to Another Disorder 69

Classifications:



External Ids:

Summaries for Secondary Adrenal Insufficiency

NIH Rare Diseases : 49 Adrenal insufficiency is an endocrine disorder that occurs when the adrenal glands do not produce enough of certain hormones. Secondary adrenal insufficiency occurs when the pituitary gland (a pea-sized gland at the base of the brain) fails to produce enough adrenocorticotropin (ACTH), a hormone that stimulates the adrenal glands to produce the hormone cortisol. The lack of these hormones in the body can be caused by reduction or cessation of corticosteroid medication, the surgical removal of pituitary tumors, or changes in the pituitary gland. Symptoms of secondary adrenal insufficiency may include severe fatigue, loss of appetite, weight loss, nausea, vomiting, diarrhea, muscle weakness, irritability, and depression. Treatment includes replacing the hormones that the adrenal glands are not making. The dose of each medication is adjusted to meet the needs of each affected individual. Last updated: 8/25/2015

MalaCards based summary : Secondary Adrenal Insufficiency, also known as hypocortisolism secondary to another disorder, is related to turner syndrome and hypopituitarism. An important gene associated with Secondary Adrenal Insufficiency is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and Adipogenesis. The drugs Epinephrine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and brain, and related phenotype is renal/urinary system.

Related Diseases for Secondary Adrenal Insufficiency

Diseases in the Acute Adrenal Insufficiency family:

Secondary Adrenal Insufficiency

Diseases related to Secondary Adrenal Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 turner syndrome 29.5 IGF1 IGFBP3
2 hypopituitarism 28.7 IGF1 IGFBP3 INS
3 insulin-like growth factor i 28.7 IGF1 IGFBP3 INS
4 central nervous system organ benign neoplasm 10.2 AVP IGF1
5 pituitary hormone deficiency, combined, 2 10.2 AVP IGF1
6 slipped capital femoral epiphysis 10.1 IGF1 IGFBP3
7 pituitary adenoma 1, multiple types 10.1 IGF1 IGFBP3
8 diffuse idiopathic skeletal hyperostosis 10.1 IGF1 IGFBP3
9 osteoporosis, juvenile 10.1 IGF1 IGFBP3
10 mammographic density 10.1 IGF1 IGFBP3
11 isolated growth hormone deficiency, type ib 10.1 IGF1 IGFBP3
12 acid-labile subunit deficiency 10.1 IGF1 IGFBP3
13 laron syndrome 10.0 IGF1 IGFBP3
14 osteogenesis imperfecta, type i 10.0 IGF1 IGFBP3
15 growth hormone deficiency 10.0 IGF1 IGFBP3
16 exudative vitreoretinopathy 1 10.0 IGF1 IGFBP3
17 colorectal adenoma 10.0 IGF1 IGFBP3
18 nutritional deficiency disease 10.0 IGF1 IGFBP3
19 male reproductive organ cancer 10.0 IGF1 IGFBP3
20 breast disease 10.0 IGF1 IGFBP3
21 chromophobe adenoma 9.9 AVP INS
22 reproductive organ cancer 9.9 IGF1 IGFBP3
23 sheehan syndrome 9.9 IGF1 INS
24 silver-russell syndrome 9.9 IGF1 IGFBP3
25 donohue syndrome 9.9 IGF1 INS
26 diabetes insipidus 9.9 AVP INS
27 autosomal dominant polycystic kidney disease 9.9 AVP IGF1
28 rubeosis iridis 9.9 IGF1 INS
29 endocrine pancreas disease 9.9 IGF1 INS
30 anovulation 9.9 IGF1 INS
31 thyroid gland disease 9.9 IGF1 INS
32 gonadal disease 9.9 IGF1 INS
33 hyperandrogenism 9.9 IGF1 INS
34 craniopharyngioma 9.9 IGF1 INS
35 cell type benign neoplasm 9.9 IGF1 INS
36 noonan syndrome 1 9.8 IGF1 IGFBP3
37 urinary system disease 9.8 AVP INS
38 spinal cord injury 9.8
39 sleep apnea 9.8 IGF1 INS
40 microvascular complications of diabetes 5 9.8 IGF1 INS
41 overnutrition 9.8 IGF1 INS
42 glucose metabolism disease 9.8 IGF1 INS
43 acquired metabolic disease 9.8 IGF1 INS
44 ovarian disease 9.7 IGF1 INS
45 pituitary adenoma 9.7
46 pituitary carcinoma 9.7
47 adenoma 9.7
48 renal cell carcinoma, nonpapillary 9.7
49 hyperthyroidism 9.7
50 stiff-person syndrome 9.7

Graphical network of the top 20 diseases related to Secondary Adrenal Insufficiency:



Diseases related to Secondary Adrenal Insufficiency

Symptoms & Phenotypes for Secondary Adrenal Insufficiency

MGI Mouse Phenotypes related to Secondary Adrenal Insufficiency:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 AVP IGF1 IGFBP3 INS

Drugs & Therapeutics for Secondary Adrenal Insufficiency

Drugs for Secondary Adrenal Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 51-43-4 5816
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-23-7 657311 5754
3 Cisatracurium Approved, Experimental Phase 4 96946-41-7
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Etomidate Approved Phase 4 33125-97-2 667484 36339
7
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
8 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 329-65-7
9
Budesonide Approved Phase 4 51333-22-3 5281004 63006
10
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
11
Menthol Approved Phase 4,Early Phase 1 2216-51-5 16666
12
Desoximetasone Approved Phase 4,Phase 2 382-67-2 5311067
13
Clobetasol Approved, Investigational Phase 4,Phase 2 25122-41-2, 25122-46-7 5311051 32798
14
Butyric Acid Experimental, Investigational Phase 4,Early Phase 1 107-92-6 264
15
Atracurium Phase 4 64228-79-1 47319
16 Analgesics Phase 4
17 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Central Nervous System Depressants Phase 4
19 Adjuvants, Anesthesia Phase 4
20 Cholinergic Agents Phase 4
21 Narcotics Phase 4
22 Cholinergic Antagonists Phase 4
23 Neuromuscular Agents Phase 4
24 Neuromuscular Blocking Agents Phase 4
25 Neuromuscular Nondepolarizing Agents Phase 4
26 Neurotransmitter Agents Phase 4,Phase 3,Early Phase 1
27 Cortisol succinate Phase 4,Phase 2,Phase 3,Early Phase 1
28 Analgesics, Opioid Phase 4
29 Anesthetics Phase 4
30 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
36 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Early Phase 1
37 Hydrocortisone acetate Phase 4,Phase 2,Phase 3,Early Phase 1
38 Hypnotics and Sedatives Phase 4
39 Epinephryl borate Phase 4,Phase 2,Phase 3,Early Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41
Cortisone Phase 4 53-06-5 222786
42
Salmeterol xinafoate Phase 4 94749-08-3 56801
43
Fluticasone Phase 4 80474-14-2, 90566-53-3 22833648 62924
44 Respiratory System Agents Phase 4,Phase 3,Phase 1,Early Phase 1
45 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4
46 Adrenergic Agents Phase 4,Phase 3,Early Phase 1
47 Adrenergic Agonists Phase 4,Phase 3,Early Phase 1
48 Adrenergic alpha-Agonists Phase 4,Phase 3,Early Phase 1
49 Adrenergic beta-2 Receptor Agonists Phase 4
50 Mydriatics Phase 4,Phase 3,Early Phase 1

Interventional clinical trials:

(show all 48)

# Name Status NCT ID Phase Drugs
1 THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients Unknown status NCT02111265 Phase 4 Remifentanil;Cisatracurium;Sufentanil
2 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
3 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
4 Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma Completed NCT00238927 Phase 4 inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)
5 Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01186653 Phase 4 budesonide / formoterol;fluticasone/salmeterol
6 Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% Recruiting NCT03212963 Phase 4 Halobetasol Topical Lotion
7 Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis Recruiting NCT02340169 Phase 4 Topicort® (desoximetasone) Topical Spray, 0.25%
8 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
9 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
10 Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency Completed NCT00575341 Phase 3 Dehydroepiandrosterone;placebo
11 Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Completed NCT00060398 Phase 3 dexamethasone
12 DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis Recruiting NCT02527421 Phase 3 DFD01 Spray
13 Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis Completed NCT01232543 Phase 2 Product 0405
14 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. Completed NCT02932891 Phase 2 DSXS topical
15 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS Completed NCT02933528 Phase 2 DSXS Topical product
16 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Completed NCT02601469 Phase 2 DSXS
17 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression Completed NCT01698333 Phase 2 122-0551
18 HPA Axis Study in Japanese Adults Completed NCT01407510 Phase 2 Mapracorat
19 HPA Axis Study in Adults Completed NCT01408511 Phase 2 Mapracorat
20 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis Completed NCT02595008 Phase 2 DSXS
21 An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris Completed NCT01831960 Phase 2 cortexolone 17α-propionate
22 Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product Completed NCT02933502 Phase 2 DSXS topical product
23 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study Completed NCT01043393 Phase 2 Desoximetasone 0.25% spray
24 DFD06 Cream vs Comp01 Cream HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Completed NCT02131324 Phase 2 DFD06 Cream;Comp01
25 Dexamethasone to Treat Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
26 Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis Completed NCT01166646 Phase 2 Halobetasol Proprionate Lotion 0.05%;Halobetasol Proprionate Cream 0.05%
27 Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Completed NCT00004990 Phase 2 Dexamethasone
28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Recruiting NCT02932878 Phase 2 DSXS topical
29 An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris Recruiting NCT02720627 Phase 2 cortexolone 17α-propionate
30 Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 Recruiting NCT03179605 Phase 2 DFD06
31 Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis Suspended NCT03245385 Phase 2 Treatment with Halobetasol propionate 0.05% topical spray
32 Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis Withdrawn NCT03298581 Phase 2 Halobetasol Propionate
33 Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers Completed NCT00936793 Phase 1 Darunavir;Ritonavir;Beclomethasone Dipropionate HFA
34 Metabolic and Endocrine Effects of Repeated Epidural and Sacroiliac Joint Corticosteroid Injections Unknown status NCT01717430
35 Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy Completed NCT01209507
36 Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome Completed NCT02368379
37 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate Completed NCT00575029 megestrol acetate
38 Intra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis Completed NCT01799408
39 Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function Completed NCT00561236
40 Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis Completed NCT00552487 synacthen
41 The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene Recruiting NCT03140761
42 Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests Recruiting NCT02818660 Synachten
43 Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency Recruiting NCT03000231
44 The PIT-TBI Pilot Study Active, not recruiting NCT02480985
45 Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess Not yet recruiting NCT01422707 Early Phase 1 Hydrocortisone
46 Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction Not yet recruiting NCT01422733 Early Phase 1 Hydrocortisone;dexamethasone;Cosyntropin;rhCG
47 Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess Not yet recruiting NCT01422096 Early Phase 1 Leuprolide
48 The Effect of Etomidate on Outcomes of Trauma Patients Withdrawn NCT00938990 Etomidate;Midazolam

Search NIH Clinical Center for Secondary Adrenal Insufficiency

Genetic Tests for Secondary Adrenal Insufficiency

Anatomical Context for Secondary Adrenal Insufficiency

MalaCards organs/tissues related to Secondary Adrenal Insufficiency:

38
Pituitary, Adrenal Gland, Brain, Testes, Prostate, Thyroid, Spinal Cord

Publications for Secondary Adrenal Insufficiency

Articles related to Secondary Adrenal Insufficiency:

(show top 50) (show all 56)
# Title Authors Year
1
Evaluation of the frequency of adrenal crises and preventive measures in patients with primary and secondary adrenal insufficiency in Switzerland. ( 29376554 )
2018
2
Primary Hypothyroid and Secondary Adrenal Insufficiency-Searching the Missing Link. ( 28571201 )
2017
3
Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial. ( 28686664 )
2017
4
National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency. ( 28351092 )
2017
5
Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. ( 28945828 )
2017
6
Gastric cancer with pituitary metastasis presenting as symptomatic secondary adrenal insufficiency: A case report. ( 28421712 )
2017
7
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate: Case report. ( 29062559 )
2017
8
Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. ( 28750490 )
2017
9
GroupA 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality. ( 29174931 )
2017
10
Characterization of Cortisol Secretion Rate in Secondary Adrenal Insufficiency. ( 29264545 )
2017
11
Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. ( 28871578 )
2017
12
A case of stiff-person syndrome due to secondary adrenal insufficiency. ( 28552871 )
2017
13
A Case of Psychosis in a Patient with Secondary Adrenal Insufficiency: A Possible Etiological Role of a Hypocortisolemic-induced Increase in Proinflammatory Cytokines. ( 29344425 )
2017
14
Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. ( 26928716 )
2016
15
Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? ( 27211575 )
2016
16
Pituitary Antibodies in an Adolescent with Secondary Adrenal Insufficiency and Turner Syndrome. ( 27355580 )
2016
17
Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal Insufficiency. ( 26676337 )
2016
18
Reversible Cardiomyopathy Accompanied by Secondary Adrenal Insufficiency. ( 26920218 )
2016
19
"Petrified Ears" in Secondary Adrenal Insufficiency. ( 27042511 )
2016
20
Large-Dose Glucocorticoid Induced Secondary Adrenal Insufficiency in Spinal Cord Injury. ( 28119833 )
2016
21
Mifepristone Accelerates HPA Axis Recovery in Secondary Adrenal Insufficiency. ( 27516913 )
2016
22
Esophageal eosinophilia in secondary adrenal insufficiency. ( 27186162 )
2016
23
Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. ( 26816449 )
2015
24
Opioid-induced secondary adrenal insufficiency presenting as hypercalcaemia. ( 26161260 )
2015
25
Concomitant giant cell arteritis and secondary adrenal insufficiency. ( 26169623 )
2015
26
Acute psychosis in the course of treatment of acute adrenal crisis with hydrocortisone in the patient with secondary adrenal insufficiency - a case study. ( 26488344 )
2015
27
Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. ( 25656494 )
2015
28
The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency--results from a randomized controlled trial. ( 25705800 )
2015
29
A Case of Primary and Secondary Adrenal Insufficiency in Children. ( 26092585 )
2015
30
Secondary adrenal insufficiency: an overlooked cause of hyponatremia. ( 25699130 )
2015
31
Phosphoglucomutase-1 deficiency: Intrafamilial clinical variability and common secondary adrenal insufficiency. ( 26768186 )
2015
32
Hyponatremia due to Secondary Adrenal Insufficiency Successfully Treated by Dexamethasone with Sodium Chloride. ( 26319655 )
2015
33
Primary vs secondary adrenal insufficiency: ACTH-stimulated aldosterone diagnostic cut-off values by tandem mass spectrometry. ( 25620457 )
2015
34
Flexion contractures of the legs as the manifestation of secondary adrenal insufficiency due to Sheehan's syndrome. ( 22996815 )
2014
35
Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. ( 23778239 )
2014
36
Health-related quality of life in primary and secondary adrenal insufficiency. ( 25252879 )
2014
37
Secondary adrenal insufficiency after glucocorticosteroid administration in acute spinal cord injury: a case report. ( 24969098 )
2014
38
Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. ( 25513635 )
2014
39
Acute secondary adrenal insufficiency as the presenting manifestation of small-cell lung carcinoma. ( 24532238 )
2014
40
Inhaled corticosteroids and secondary adrenal insufficiency. ( 25674179 )
2014
41
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. ( 24455332 )
2013
42
Topical corticosteroids and secondary adrenal insufficiency: a relationship in the shade. ( 24076040 )
2013
43
Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. ( 22930487 )
2012
44
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. ( 23034783 )
2012
45
Autoimmune hyperthyroidism due to secondary adrenal insufficiency: resolution with glucocorticoids. ( 20841313 )
2011
46
Malakoplakia of the kidney extending to the descending colon in a patient with secondary adrenal insufficiency: a case report. ( 22745875 )
2011
47
Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. ( 20456080 )
2010
48
Flexion contractures in secondary adrenal insufficiency. ( 19795178 )
2010
49
Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. ( 19585406 )
2009
50
[Secondary adrenal insufficiency after local injections of triamcinolone acetonide]. ( 19197811 )
2009

Variations for Secondary Adrenal Insufficiency

Expression for Secondary Adrenal Insufficiency

Search GEO for disease gene expression data for Secondary Adrenal Insufficiency.

Pathways for Secondary Adrenal Insufficiency

GO Terms for Secondary Adrenal Insufficiency

Cellular components related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 AVP IGF1 IGFBP3 INS PGM1
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.7 AVP IGF1 INS
2 positive regulation of gene expression GO:0010628 9.69 AVP IGF1 INS
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.56 IGF1 INS
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 IGF1 INS
5 glucose metabolic process GO:0006006 9.54 INS PGM1
6 cellular protein metabolic process GO:0044267 9.54 IGF1 IGFBP3 INS
7 positive regulation of DNA replication GO:0045740 9.49 IGF1 INS
8 activation of protein kinase B activity GO:0032148 9.48 IGF1 INS
9 positive regulation of glucose import GO:0046326 9.46 IGF1 INS
10 ERK1 and ERK2 cascade GO:0070371 9.43 AVP IGF1
11 positive regulation of mitotic nuclear division GO:0045840 9.4 IGF1 INS
12 positive regulation of glycolytic process GO:0045821 9.32 IGF1 INS
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.26 AVP IGF1
14 positive regulation of glycogen biosynthetic process GO:0045725 9.16 IGF1 INS
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.96 IGF1 IGFBP3
16 positive regulation of MAPK cascade GO:0043410 8.8 IGF1 IGFBP3 INS

Molecular functions related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.16 IGF1 INS
2 insulin-like growth factor receptor binding GO:0005159 8.96 IGF1 INS
3 hormone activity GO:0005179 8.8 AVP IGF1 INS

Sources for Secondary Adrenal Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....